首页
期刊简介
编 委 会
期刊订阅
百年学会 医星璀璨
名院风范
学科风华
菁英风采
投稿须知
过刊浏览
联系我们
篇名
关键词
作者
作者单位
摘要
关键词
注册本刊作者
作者投稿查稿
专家远程审稿
编辑在线审稿
编务办公专区
主编办公专区
下载文档
《上海医学》审稿费代缴委托书
《上海医学》杂志2024年征订启事
《上海医学》期刊编审系统审稿专家使用手册
工作动态
03-05
《上海医学》杂志2024年度“春蕾杯”论文评比征文通知
06-14
创新驱动,培育人才—《上海医学》2021年度春蕾计划评审结果揭晓
01-21
《上海医学》期刊影响力指标和学科排名取得显著提升
01-20
《上海医学》恭祝大家新年快乐!
08-18
作废声明
联系方式
发行周期:
月刊
主管单位:
上海市卫生健康委员会
主办单位:
上海市医学会
编辑出版:
《上海医学》编辑部
联系地址:
上海市北京西路1623号
邮编:
200040
电话:
021-62178606
传真:
021-62178606
邮箱:
smasmj@shsma.org.cn
ISSN:
ISSN0253-9934
CN:
CN31-1366/R
收款账号:
1001255309008900719
账户名:
上海市医学会
开户行:
工商银行上海市静安寺支行
友情链接
上海市医学会
当前位置:首页 >
过刊浏览
->
2012年第3期
阿托伐他汀对慢性心衰患者外周血TLR4表达的影响
Effects of Atorvastatin on TLR4 Expression on Circulating Monocytes in Patients with Chronic Heart Failure
浏览(2443) 下载(0)
DOI:
作者:
吴炎
吴炎、蒲红
作者单位:
解放军85医院心血管内科
the 85 Hospital of the People's Liberation Army
关键词:
慢性心衰,TLR,阿伐他汀,免疫
Chronic heart failure; Toll—like receptor4; statin; immune
摘要:
目的:探讨慢性充血性心力衰竭(CHF)患者外周血单个核细胞Toll样受体4(TLR4)表达改变情况及其阿托伐他汀的干预效应。方法:选取住院的慢性充血性心力衰竭患者80例,其中40例为标准药物治疗组,另外40名在标准治疗基础上给与阿托伐他汀20mg/日,治疗前和治疗一月后用流式细胞仪检测外周血单核细胞表面TLR4的表达,ELISA法检测血清TNFα水平;并对TLR4的表达与血清TNFα水平进行相关性分析。结果:CHF患者外周循环单个核细胞TLR4表达水平较对照组明显增高(p<0.05),并且与血清TNFα水平呈正相关;与标准治疗比,标准治疗基础上给与阿托伐他汀20mg/日治疗一个月,可在明显降低外周血单核细胞TLR4的表达和血清TNFα水平。结论:TLR4表达可能与CHF发生有关,阿托伐他汀可显著降低外周血单核细胞TLR4的表达,推测阿托伐他汀的抗炎症免疫作用与抑制TLR4介导的炎症免疫反应有关。
Objective:To study the changes of Toll—like receptor4 (TLR4) on peripheral blood mononuclear cells(PBMCs) and their role in the pathogenesis of chronic heart failure(CHF). Methods Eighty CHF patients were recruited.40 patients were randomized to routine anti-heart failure treatment group or atorvastatin group(20 mg/d) on top of routine anti-heart failure treatment for one month.40 age-matched healthy subjects were regarded as normal control. TLR4 expression on monocytes were measuered via flow-cytometry before and after one month treatment.Serum level of TNFα were meathored by ELIZA. Results Before treatment, TLR4 expression on monocytes were higher in routine anti-heart failure treatment group and atorvastatin treatment group than normal controls. ( 3.8±1.9 vs.3.7士2.1 vs 1.8±0.5. P<0.05). After one month treatment with atorvastatin, TLR4 expression were significantly decreased compared with routine anti-heart failure treatment group.( 3.4±1.1 vs. 2.2±1.8) . Serum TNFα level correlated with TLR4 expression level (r=0.076, P<0.05). Conclusion CHF is associated with enhanced expression of TLR4 in circulating monocytes. Treatment with atorvastatin with short time could significantly decreased TLR4 expression. The anti-inflammatory effect by atorvastatin may be partially dued to down-regulating the expression of TLR4.